👉We deeply mourn the loss of our dear friend, loving big sister, co-fellow, world expert, the brilliant light, amazing all-time Dr .@rachnatshroff | May she rest in peace. May her wonderful legacy carry on forever, may we never forget @rachnatshroff 🙏 medicine.arizona.edu/news/20…

Congratulations @montypal on the KCA Eugene P. Schonfeld Award! 🎉 An extraordinary mentor, leader, and kidney cancer researcher whose work has changed how we treat RCC, and who generously lifts up colleagues worldwide. Thoroughly deserved. #IKCSNA26 #kidneycancer

Pick any medical specialty other than your own. Who’s the most famous physician in it? You probably can’t name one. Almost none of us will be known outside our field, and even those who achieve real professional fame are mostly forgotten within a few decades. Fame is a poor reason to devote your life to medicine. The work itself matters more: caring for patients, discovering new knowledge, and teaching the next generation.

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

Promotion to Professor — an accomplishment I have worked for over many years, effective today. Thanks @suzanneconzenmd @carlosarteagamd & all colleagues around the world who wrote/called for me. Grateful beyond words. @drchoueiri @montypal @albigesL @ERPlimackMD @Daniel_J_George

🎉Beyond thrilled to have joined and to be working with the incredible @DrChoueiri et al @DanaFarber! A very special thank you to @montypal for his tremendous mentorship and support! And many thanks to all the other mentors who have helped me along the way 🙏 😅 Looking back as a PGY-14, it only took two internal medicine residencies, a few research years, and an oncology fellowship to get here. But I enjoyed every bit of the journey and met so many incredible people!! @UniversiteEge @YaleIMed @UTMDAnderson @cityofhope @IMG_Oncologists @ASCOTECAG @ASCO @DanaFarber_GU @ConquerCancerFd @kureit @kidneycan @KidneyCancer

Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber 1) Dr. Nazli Dizman @NazliDizman 2) Dr. Brian Russell @brian_russell39 3) Dr. Hamid Emamekhoo @HamidEmamekhoo 4) Pr. Neeraj Agarwal @neerajaiims They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology. Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands. Welcome to @CityOfBoston and @DanaFarber!

JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯 Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma. For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy. Personalized cancer vaccines are moving from promise to reality. Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏 Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (nature.com/articles/s41586-0…) merck.com/news/merck-and-mod…

Metrics from #ASCO26 via @OncoAlert @ASCO

Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/s…

JUST IN: VOLGA Phase III is (+)=>Neoadjuvant Durva+EV and adjuvant Durva alone showed EFS & OS benefit. The shorter period of EV is a very attractive option! @DanaFarber_GU @OncoAlert @OncBrothers @AstraZeneca @tompowles1 @AUC3_Official

🎉Incredibly proud of this publication and grateful for the leadership of @salvolarosa @BataiKen @PavlosMsaouel and other contributors who made this important research possible. Our paper is out today with FREE access! 🔗mdpi.com/2072-6694/18/9/1454

One of our favorite sessions at #IKCSEU26: European Women in RCC & Allies 💚🧡 today with #AthinaChristopolou @TiansterZhang @drulkav @AlbigesL @ERPlimackMD @lisapic

Always a dynamic discussion during KCA Think Tank meetings where many of our most impactful programs and moonshot initiatives have sparked! Thanks to our #IKCSEU26 TT presenters #LarsLund @grantissimus @srossi725 @MichaelStaehler @RCCadvocate #axelbex @salvolarosa @GEVaughan1

Albert, great discussion with a powerhouse prostate cancer panel—Dr. Maha Hussain, Dr. Sandy Srinivas, Dr. Dan Petrylak, Dr. Ulka Vaishampayan, and Dr. Ben Maughan 👏 We learned so much from your case discussion at #MatosGU26. This is how we all get better. @AJangMD @PGrivasMDPhD @mecmededucation 💡 💥 Loved this moment. Great job Albert! #Oncology #MedEd #ProstateCancer @DanielPetrylak @sandysrimd @DrVaishampayan @maughanonc @oncodaily @urotoday @Larvol

Awesome talk by @MVossMD on non clear cell RCC covering different histology types: evolving landscape but need specific trials for each histology! @ZakhariaYousef @CParkMD @EddieSantosMD @LuisRaezMD @mecmededucation @ADESAIONCMD @sandysrimd @ChadTangMD @HHammersMD @JadChahoud

We, @DanaFarber_GU, and @MGBUrology enjoyed very much hosting @JoshMeeks from @NM_Urology —Josh is a super star surgeon-scientist who is pushing the envelope in bladder cancer with a focus on epigenetics! He also ❤️ @RedSox !